SAN FRANCISCO, Nov. 16, 2013 /PRNewswire/ -- Cardiovascular disease is the #1 killer of Americans, yet 50% of hospital admissions for coronary artery disease have normal LDL-cholesterol.(i) The Lipoprotein(a) Foundation is revealing this hidden risk for patients.
"Patients with elevated Lipoprotein(a) [Lp(a)] levels have an increased risk of cardiovascular disease, including heart attack, stroke and peripheral arterial disease(ii). Lp(a) is a genetically-determined condition that is not responsive to lifestyle changes. Elevated Lp(a) levels are present in about 30% of the population at large(iii). Since Lp(a) is not currently routinely measured by physicians, many patients are unaware that they have elevated levels. Lp(a) can be measured with a routine lipid blood panel, but there is no adequate treatment currently to lower levels. Knowledge of elevated Lp(a) levels may motivate physicians to treat their patients' risk factors more aggressively and patients to live a heart healthy lifestyle until specific therapies can be developed and tested clinically," said Sotirios Tsimikas, M.D., Professor of Medicine and Director of Vascular Medicine at the University of California San Diego. "The Lipoprotein(a) Foundation is a needed resource for education of patients and their families that aims to raise public awareness of the potential risk of elevated Lp(a) levels that will hopefully lead to prevention and early treatment of cardiovascular disease."
"It is now documented that elevated Lp(a) levels not only cause heart attacks, but also aortic valve stenosis, another serious and potentially deadly heart disease. Therefore like those with heart attacks, individuals with aortic valve stenosis and their family members should have Lp(a) measured," said Professor, Chief Physician Børge Nordestgaard from Copenhagen University Hospital in
'/>"/> SOURCE The Lipoprotein(a) Foundation
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. The Hidden Complications of Single-Sided Deafness
2. Consumers Are Advised to Be Aware of Hidden Costs in Some Discount Dental Plans
3. Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
4. ChanRx to Present Results of Phase IIb Study in Atrial Fibrillation at the 2013 American Heart Association Scientific Sessions
5. 1,200th Worldwide Implant of the SynCardia Total Artificial Heart Occurs in Indiana
6. HeartWare Presentation At The Canaccord Genuity Medical Technology & Diagnostics Forum To Be Webcast
7. Helping New Yorkers Prevent Heart Attacks: Itamar Medical Joins The Fight With New Campaign
8. Millennium HealthCare Launches its Nation Wide Roll Out with Heart Smart Inc.
9. HeartWare International Reports $54.8 Million In Third Quarter 2013 Revenue; 140% Increase From Third Quarter Of 2012
10. Preventing Heart Disease One Step at a Time
11. Study Finds Pre-Hospital Administration Of Bivalirudin Substantially Improves Outcomes Compared To Heparin In Heart Attack Patients